Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15384984 | 0.86 | TNKS2 (0.41) | KDM1AL3MBTL1TNKS2 | |
| SCHEMBL10976808 | 0.85 | CYP17A1 (0.48) | KDM1AL3MBTL1TUBB1FFAR1PPARD | |
| SCHEMBL17254338 | 0.85 | KDM1A (0.47) | KDM1AL3MBTL1TUBB1FFAR1PPARG | |
| SCHEMBL3126227 | 0.85 | KDM1A (0.51) | KDM1AL3MBTL1TUBB1FFAR1PPARG | |
| SCHEMBL15803458 | 0.85 | KDM1A (0.47) | KDM1AL3MBTL1TUBB1CALM1 | |
| SCHEMBL14734486 | 0.85 | KDM1A (0.47) | KDM1AL3MBTL1TUBB1FFAR1PPARG | |
| SCHEMBL19602416 | 0.85 | CSNK2A1 (0.47) | L3MBTL1TNKS2KDM4EALDH1A1HTT | |
| SCHEMBL8377141 | 0.84 | HTT (0.49) | KDM1AL3MBTL1KDM4EALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL3113585 | 0.83 | KDM1A (0.50) | KDM1AL3MBTL1TUBB1FFAR1PPARG | |
| SCHEMBL6468437 | 0.83 | S1PR1 (0.49) | L3MBTL1TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3311835-B1 | ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS AND ANTIANGIOGENIC AGENTS FOR THE TREATMENT OF CANCER | THRESHOLD PHARMACEUTICALS INC (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3311835-A1 | ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS AND ANTIANGIOGENIC AGENTS FOR THE TREATMENT OF CANCER | Threshold Pharmaceuticals Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9527876-B2 | Prodrugs of bicyclic substituted pyrimidine type PDE-5 inhibitors | Xuanzhu Pharma Co., Ltd. (CN) | 2016-12-27 | — | — | US | disclosed |
| US-9359371-B2 | Bicyclic substituted pyrimidine compounds | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-20160046654-A1 | Prodrugs Of Bicyclic Substituted Pyrimidine Type PDE-5 Inhibitors | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2016-02-18 | — | — | US | disclosed |
| WO-2015171647-A1 | TREATMENT OF CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150232474-A1 | Bicyclic Substituted Pyrimidine Compounds | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2015-08-20 | — | — | US | disclosed |
| WO-2014154168-A1 | BICYCLIC SUBSTITUTED PYRIMIDINE PDE-5 INHIBITOR PRODRUG | 山东轩竹医药科技有限公司 (CN) | 2014-10-02 | — | — | WO | disclosed |
| US-8664204-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130303778-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. | 2013-11-14 | — | — | US | disclosed |
| US-8507464-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| WO-2012142520-A2 | UNIT DOSE FORM FOR ORAL ADMINISTRATION | THRESHOLD PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012135757-A2 | METHODS FOR TREATING CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012009288-A2 | ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS AND ANTIANGIOGENIC AGENTS FOR THE TREATMENT OF CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012006032-A2 | TREATMENT OF BLOOD CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| EP-2019825-B9 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2011-01-26 | — | — | EP | disclosed |
| EP-2019825-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2010-09-01 | — | — | EP | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| WO-2007131350-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-22 | — | — | WO | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | KDM1A 1205/4885L3MBTL1 4353/4885TUBB1 913/4885 |
| US-20150232474-A1 | Bicyclic Substituted Pyrimidine Compounds | DPYD, UMPS, TYMP | KDM1A 4526/4885L3MBTL1 4350/4885TUBB1 3485/4885 |
| US-20130303778-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | TYMP, PAICS, PNP | KDM1A 3384/4885L3MBTL1 745/4885TUBB1 3912/4885 |
| US-20160046654-A1 | Prodrugs Of Bicyclic Substituted Pyrimidine Type PDE-5 Inhibitors | PDE5A, PDE3A, PDE7A | KDM1A 2418/4885L3MBTL1 4480/4885TUBB1 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.